Medpace’s European expansion continues in UK

By Zachary Brennan contact

- Last updated on GMT

Medpace’s European expansion continues in UK

Related tags: European union

CRO Medpace has tripled the size of its Stirling, Scotland office with a new office, also in Stirling, that will allow for growth in data management, biostatistics, quality assurance, regulatory affairs, clinical operations and safety services.

The UK offices in London and Stirling now house nearly 130 Medpace employees as the company has increased its expansion efforts in Europe over the past few years.

The European activities have included adding additional clinical research professionals and expanding facilities in the UK, Poland, Russia, France, Germany and other expected expansions this year and next year in Leuven, Belgium, Prague and Madrid.

We have been adding and enlarging our office spaces globally, however Europe continues to be a growth market for us – enabling us to better support a number of large global studies on behalf of our sponsors​,” spokeswoman Mary Kuramoto told us. “Our key therapeutic areas are endocrinology, cardiovascular, oncology, and infectious disease….Medpace now has 12 offices in the EU and a Central Lab in Belgium​.”

Ohio-based Medpace established its first European office in the Czech Republic in 2005, and then boosted its device offerings in the region with the acquisition of Meditech​ in 2012. Last year, UK-based private equity firm Cinven acquired Medpace for $915m, saying the company is particularly attractive given its focus on small- and mid-sized biotech, pharma and med device clients. The company also expanded into Asia last year by opening a new central lab in Singapore​.

Medpace employees in Europe now account for over one third of its 2000 staffers. The company says it will continue to grow and offer services for studies in oncology, cardio metabolic, infectious disease, CNS, and other therapeutic areas.

Related news

Show more

Related products

show more

Overcoming Challenges of Clinical Data Review

Overcoming Challenges of Clinical Data Review

PerkinElmer | 10-Jun-2021 | Technical / White Paper

Clinical data review is intrinsic to clinical development, assuring patient safety, determining drug efficacy, and assessing data quality. It involves...

How clinical trial software can optimize trials

How clinical trial software can optimize trials

Formedix | 09-Jun-2021 | Technical / White Paper

This article explains the different types of clinical trial software available, and how it can be used to optimize the end to end clinical trials design...

Transforming Clinical Development

Transforming Clinical Development

PerkinElmer | 01-Jun-2021 | Technical / White Paper

The estimated cost of bringing a drug to market in the U.S. according to JAMA is $1 billion.1 The extreme cost of clinical trials urge biopharmaceutical,...

Related suppliers

Follow us


View more